Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CLIC-2201

Phase 1Biologic

BBritish Columbia Cancer Agency

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

B-Cell LeukemiaRecruiting

B-Cell LeukemiaPhase 1

Recruiting

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

B-Cell Leukemia

NCT06208735

Clinical

Trials by Indication[1]

B-Cell Leukemia1 trial

CLIC-02: A Phase I Trial of CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

Recruiting·BBritish Columbia Cancer Agency·Phase 1·NCT06208735·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CLIC-2201. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CLIC-2201 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CLIC-2201. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — British Columbia Cancer Agency company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: BBritish Columbia Cancer Agency

Related News